8-K Announcements
6Material company update
May 14, 2026·SEC
Material company update
May 7, 2026·SEC
Material company update
Apr 2, 2026·SEC
Curanex Pharmaceuticals Inc Common Stock(CURX)Earnings, Financials & Key Ratios
CURX•NASDAQ
$0.27
Price updated Jun 27, 2026
AboutCuranex Pharmaceuticals Inc, a developmental stage pharmaceutical company, discovers, develops, and commercializes botanical drugs to treat patients suffering from inflammatory diseases. It develops Phyto-N for various therapeutic areas, including ulcerative colitis, atopic dermatitis, COVID-19, diabetes, nonalcoholic fatty liver disease, gout, and acne. The company was formerly known as Fordman Pharma Inc. and changed its name to Curanex Pharmaceuticals Inc in November 2023. The company was founded in 1996 and is headquartered in Jericho, New York.Show more
- Revenue$0
- EBITDA-$4M-1332.5%
- Net Income-$4M-1068.8%
- EPS (Diluted)-0.17-1207.7%
- ROE-72.09%+43.8%
CURX Price & Volume
Curanex Pharmaceuticals Inc Common Stock (CURX) stock price & volume — 10-year historical chart
Loading chart...
Persistent Cash Burn Threatens Botanical Pipeline Viability
Investment Thesis • Updated 2026Q1
VerdictNegative
Growth:Contracting
Profitability:Negative
Financial:Vulnerable
Cash Flow:Burning
Primary Risk:Insufficient capital for development
Key Thesis Takeaways
- Curanex Pharmaceuticals remains a pre-revenue entity facing significant structural challenges in scaling its botanical drug candidates to meet rigorous FDA standards.
- The company's reliance on external capital is underscored by a rapidly depleting cash position and widening operating losses that reached $3.2 million in 2026Q1.
- Investors should remain cautious as the firm lacks the necessary manufacturing infrastructure and commercial revenue to offset its accelerating research and development expenditures.
Verdict Logic
the company's cash runway is rapidly contracting, with cash balances falling to $4.0 million in 2026Q1, leaving insufficient capital to support its broad clinical development pipeline.
CURX Growth Metrics
Curanex Pharmaceuticals Inc Common Stock (CURX) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-
Return on Capital
10 Years-77.55%
5 Years-77.55%
3 Years-77.55%
Last Year-70.97%
Peers Comparison
Key metrics vs top competitors for Curanex Pharmaceuticals Inc Common Stock (CURX)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $0.27 | $7.52M | -1.56 | — | — | -72.09% | — | |
| $25.32 | $4.34B | 11.06 | 11.87% | 34.3% | 35.65% | — | |
| $241.67 | $12.44B | -65.67 | 65.55% | -26.59% | -260.01% | — | |
| $23.57 | $1.74B | 7.14 | 18.52% | 118.91% | 47.59% | — | |
| $327.79 | $9.47B | -24.32 | -100% | — | -43.02% | — | |
| $63.65 | $1.24B | -6.54 | -43.89% | -284.18% | -87% | — |
Compare CURX vs Peers
Curanex Pharmaceuticals Inc Common Stock (CURX) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
CURX SEC Filings & Documents
Curanex Pharmaceuticals Inc Common Stock (CURX) SEC filings — annual & quarterly reports (10-K, 10-Q)
Get notified when CURX posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
CURX Frequently Asked Questions
Curanex Pharmaceuticals Inc Common Stock (CURX) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Is CURX profitable?
Curanex Pharmaceuticals Inc Common Stock (CURX) reported a net loss of $7.2M for fiscal year 2025.
Dividend & Returns
What is CURX's return on equity?
Curanex Pharmaceuticals Inc Common Stock (CURX) has a return on equity (ROE) of -72.1%. Negative ROE indicates the company is unprofitable.
What is Curanex Pharmaceuticals Inc Common Stock's free cash flow?
Curanex Pharmaceuticals Inc Common Stock (CURX) had negative free cash flow of $11.3M in fiscal year 2025, likely due to heavy capital investments.